• Covalon Technologies announced results from a retrospective real-world evidence analysis comparing its collagen matrix dressing with rival collagen dressings.
• Findings were presented with this announcement, based on de-identified U.S. outpatient wound-center records analyzed with Intellicure.
• In diabetic foot ulcers, the dressing showed the strongest modeled likelihood of reaching meaningful granulation coverage over time versus competitors.
• Venous leg ulcer results followed a similar pattern, supporting further evaluation of the product in hard-to-heal wounds.
• Work was funded by Covalon, framed as association evidence rather than proof of causality.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Covalon Technologies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609240700BIZWIRE_USPR_____20260924_BW302329) on September 24, 2026, and is solely responsible for the information contained therein.